Le Lézard
Classified in: Health, Business
Subject: VEN

New Challenger Onboard? Syai Health Brings the New Fashion to CGM Experience & Chronic Disease Management


Syai Health secured significant funding from AstraZeneca plc & Xiaomi Corporation.

SINGAPORE, Feb. 20, 2024 /PRNewswire/ -- Singapore-based biotech company, Syai Health, abbreviated for "Sychronise + AI", secured significant funding from leading investors like AstraZeneca plc and Xiaomi Corporation for its in-house developed AI-empowered medical devices. Originally an Oxford-Cambridge spinoff, alongside an R&D crew from top institutions and a design team from the Royal College of Art, Syai Health achieved another crucial fundraising milestone after years of dedication. Driven by a strong faith in transforming the industry (CDM), Syai's cutting-edge products, such as Continuous Glucose Monitor, promise to revolutionize home-based health management with a next-level digitalization. Syai Health is prepared to broaden the horizon and reshape the CGM experience with its user-centric product lineup empowered by AI integration.

Syai Tag CGM with cross-platform functionality.

Syai has distinguished itself in the market with its thoughtful design and data processing capabilities. The all-in-one monitoring unit can be worn discreetly on the body with its size of less than a quarter and weight of only 1.6g. Syai integrates its advanced algorithm that not only analyzes real-time glucose readings but also provides personalized feedback as a reference, making the device a responsive, considerate companion to users' health management journey. It unlocked the potential for proactive users to make informed changes to their lifestyle and overall well-being.

Syai's CGM device pairs with a user-friendly app and cloud-based data solutions that allow patients to track, retrieve, and share real-time data or reports with their healthcare providers or families for more comprehensive care. Syai transformatively positioned data as the core of its CDM strategy, where data-driven analysis & deep learning help improve the quality of life, marking a significant milestone for Syai Health.

Syai is poised to expand its reach and make its CGM devices available to global customers with the funding. The company's success in investment procurement mentioned is a testament to its prospective for growth and innovation. Regarding the upward trends of self-care and wellness management for individuals over the past few years, Syai's medical devices with advanced software systems are well-positioned to capture a significant portion of the target market and revitalize the CDM (Chronic Disease Management) experiences for customers worldwide.

About Syai

Headquartered in Singapore, Syai Health has emerged as the Transcender of CDM. For more information, visit: http://www.syai.com

For media/business inquiries, please contact: bd@syai.com

Photo - https://mma.prnewswire.com/media/2343276/Syai_Tag_CGM_cross_platform_functionality.jpg 


These press releases may also interest you

at 08:05
AlTi Global, Inc. Reports First Quarter 2024 Financial Results
AlTi Global, Inc. ("AlTi" or the "Company"), a leading independent global wealth and alternatives manager with over $70 billion in combined assets, today announced financial results for the first quarter ended March 31, 2024. A presentation of the...

at 08:05
CBL Properties Reports Strong Results for First Quarter 2024
CBL Properties announced results for the first quarter ended March 31, 2024. Results of operations as reported in the consolidated financial statements for these periods are prepared in accordance with GAAP. A description of each supplemental...

at 08:01
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
Intensity Therapeutics, Inc. ("Intensity" or "the Company") , a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase...

at 08:00
Vincent Chen Joins Lancaster Resources Board of Directors, Bolstering Expertise in Corporate Development
Lancaster Resources Inc. (FRA:6UF0) ("Lancaster") a leader in critical mineral exploration, is pleased to announce the appointment of Mr. Vincent Chen, CPA, as an independent director to its Board of Directors, effective May 9, 2024. Vincent...

at 08:00
Doman Building Materials Group Ltd. Announces Meeting Results for Election of Directors
Doman Building Materials Group Ltd. ("Doman") or the "Company") announced its director election results following its annual and special meeting of shareholders, held May 9, 2024. All of the nominees proposed as directors in the Company's...

at 08:00
LAFC makes Ontario International its Official Airport
Ontario International Airport (ONT) is now the Official Airport of Los Angeles Football Club (LAFC) through an innovative partnership with the Major League Soccer team that includes community events, LAFC visibility throughout the two terminals and...

More news about Business...


News published on and distributed by: